Anemia and Iron Management

Seminars in Dialysis

Volumn 24, Issue 5, 2011, Pages 498-503

  Besarab, Anatole ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON;

BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; IRON DEFICIENCY ANEMIA; NOTE;

ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC;

EID: 80054685236     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00983.x     Document Type: Note

References (58)

1. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
2. KDOQI: clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:471-530, 2007
3. Collins AJ, Brenner RM, Ofman JJ: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46:481-488, 2005
4. Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ: Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 14:2654-2661, 2003
5. Lacson E, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41:111-124, 2003
6. Chan K, Lafayette RA, Whittemore AS, Hlatky MA, Moran J: Facility factors dominate the ability to achieve target hemoglobin levels in hemodialysis patients. Nephrol Dial Transplant 23:2948-2956, 2008
7. Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger SL: Center effects in anemia management of dialysis patients. J Am Soc Nephrol 18:646-653, 2007
8. Reddan DN, Frankenfield DL, Klassen PS, Coladonato JA, Szczech L, Johnson CA, Besarab A, Rocco M, McClellan W, Wish J, Owen Jr WF: Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant 18:147-152, 2003
9. Drüeke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16(S7):25-28, 2001
10. Pronai W, RieglerKeil M, Silberbauer K, Stockenhuber F: Folic acid supplementation improves erythropoietin response. Nephron 71:395-400, 1995
11. Zachee P, Chew SL, Daelemans R, Lins RL: Erythropoietin resistance due to vitamin B12 deficiency: case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol 12:188-191, 1992
12. Hedayati SS: Dialysis-related carnitine disorder. Semin Dial 19:323-328, 2006
13. Brunelli SM, Goldfarb S: Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 18:1999, 2007
14. Johnson DW, Pollock CA, Macdougall IC: Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 12:321, 2007
15. Elliott J, Mishler D, Agarwal R: Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 16:94, 2009
16. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42:864, 2003
17. Handelman GJ, Levin NW: Red cell survival: relevance and mechanism involved. J Ren Nutr 20:S84, 2010
18. Costa E, Rocha S, Rocha-Pereira P, Castro E, Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A: Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. Blood Purif 26:267, 2008
19. Buemi M, Floccari F, Di Pasquale G, Cutroneo G, Sturiale A, Aloisi C, Ruello A, Romeo A, Favaloro A, Corica F, Frisina N, Anastasi G: AQP1 in red blood cells of uremic patients during hemodialytic treatment. Nephron 92:846, 2002
20. Debska-Slizien A, Owczarzak A, Lysiak-Szydlowska W, Rutkowski B: Erythrocyte metabolism during renal anemia treatment with recombinant human erythropoietin. Int J Artif Organs 27:935, 2004
21. Gambhir KK, Parui R, Agarwal V, Cruz I: The effect of hemodialysis on the transport of sodium in erythrocytes from chronic renal failure patients maintained on hemodialysis. Life Sci 71:1615, 2002
22. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469, 2002
23. Pollock C, Johnson DW, Horl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E: Pure red cell aplasia induced by erythropoiesis stimulating agents. Clin J Am Soc Nephrol 3:193, 2008
24. Macdougall IC, Casadevall N, Froissart M, Stead RB, Duliege AM, Froissart M, Eckardt KU: Treatment of erythropoietin antibody-mediated pure red cell aplasia with a novel synthetic peptide-based erythropoietin receptor agonist. N Engl J Med 361:1848-1855, 2008
25. Gershon SK, Luksenburg H, Cote TR, Braun MM: Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346:1584, 2002
26. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68:1337-1343, 2005
27. United States Renal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 2. ESRD Incidence and Prevalence. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007. Available at, accessed November 7, 2007
28. Berns JS, Elzein H, Lunn RI, Fishbane S, Meisels IS, DeOreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64:1514-1521, 2003
29. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI: Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18:3164-3170, 2007
30. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 3:133-138, 2008
31. Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall IC: Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 21:1765-1775, 2010
32. FDA: Advisory Committee briefing document joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety Risk Management Committee. Available at, accessed May 7, 2010
33. Sczcech LA, Burnhart HXS, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. Kidney Int 74:791-798, 2008
34. Weinhandl ED, Peng Y, Gilbertson DT, Bradbury BD, Collins AJ: Hemoglobin variability and mortality: confounding by disease severity. Am J Kidney Dis 57:255-265, 2011
35. Pisoni RL, Bragg-Gresham JL, Fuller DS, Morgenstern H, Canaud B, Locatelli F, Li Y, Gillespie B, Wolfe RA, Port FK, Robinson BM: Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 57:266-275, 2011
36. Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK: Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22:358-365, 2011
37. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, Feldman HI: History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol. 3:777-782, 2008
38. Department of Health and Human Services, Centers for Medicare & Medicaid Services: 42 CFR Part 413 [CMS-3206-P] RIN 0938-AP91, Medicare Program; End-Stage Renal Disease Quality Incentive Program. Available at, accessed October 12, 2010
39. Babitt JL, Lin HY: Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 55:726, 2010
40. Singh AK, Coyne DW, Shapiro W, Rizkala AR, DRIVE Study Group: Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71:1163-1171, 2007
41. Besarab A, Horl WH, Silverberg D: Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 14(Suppl 1):22, 2009
42. Bilic E, Bilic E: Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia. J Pediatr Hematol Oncol 25:675, 2003
43. Kinoshita Y, Taniura S, Shishido H, Nojima T, Kamitani H, Watanebe T: Cerebral venous sinus thrombosis associated with iron deficiency: two case reports. Neurol Med Chir (Tokyo) 46:589, 2006
44. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-2098, 2006
45. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032, 2009
46. Fleming RE, Bacon BR: Orchestration of iron homeostasis. N Engl J Med 352:1741, 2005
47. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1(Suppl 1):S9, 2006
48. Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Suppl 1):S4, 2006
49. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1:652-655, 1982
50. Theil EC: Ferritin: at the crossroads of iron and oxygen metabolism. J Nutr 133:1549S, 2003
51. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C: Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 1054:445, 2005
52. Yee J, Besarab A: Iron sucrose: an old therapy becomes new. Am J Kidney Dis 40:1111-1121, 2002
53. Bolaños L, Castro P, Falcón TG, Mouzo R, Varela JM: Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 22:67-72, 1992
54. Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34:21, 1999
55. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530, 2000
56. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21:378-382, 2006
57. Moniem KA, Bhandari S: Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Trans Alt Trans Med 1:1-7, 2007
58. Sav T, Tokgoz B, Sipahioglu MH: Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 29:423-426, 2007